ACTIV-3: Therapeutics for Inpatients With COVID-19
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
people who have been hospitalized with the infection. Participants in the study will be
treated with either a study drug plus current standard of care (SOC), or with placebo plus
current SOC.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID) University of Minnesota
Collaborators:
AIDS Clinical Trials Group AstraZeneca Brii Biosciences Limited Cardiothoracic Surgical Trials Network (CTSN) Eli Lilly and Company GlaxoSmithKline International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Kirby Institute Medical Research Council Molecular Partners AG National Heart, Lung, and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID) Pfizer Prevention and Early Treatment of Acute Lung Injury (PETAL) University of Copenhagen US Department of Veterans Affairs Vir Biotechnology, Inc. Washington D.C. Veterans Affairs Medical Center